|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C25H21F3N6O3S |
|||
| Molecular Weight | 542.53 | CAS No. | 1393466-87-9 | |
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (184.32 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | PLX8394 is a next-generation, orally available, small-molecule BRAF inhibitor with IC50 values of 3.8 nM, 14 nM and 23 nM for BRAF(V600E), WT BRAF and CRAF respectively. It has potential antineoplastic activity. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
||||||
| In vitro | PLX8394 is a next-generation, orally available small-molecule BRAFi that does not induce the RAF/MEK/ERK paradoxical activation and blocks signaling from both monomeric BRAFV600 and dimeric BRAFnon-V600 protein[1]. |
||||||
| In vivo | PLX8394 is a next-generation, orally available, small-molecule BRAF inhibitor with potential antineoplastic activity. |
Protocol (from reference)
| Cell Assay: |
|
|---|
References
Selleck's PLX8394 has been cited by 10 publications
| SB202190 Predicts BRAF-Activating Mutations in Primary Colorectal Cancer Organoids via Erk1-2 Modulation [ Cells, 2023, 12(4)664] | PubMed: 36831331 |
| Design and Synthesis of Novel 2-Acetamido, 6-Carboxamide Substituted Benzothiazoles as Potential BRAFV600E Inhibitors - In vitro Evaluation of their Antiproliferative Activity [ ChemMedChem, 2023, e202300322.] | PubMed: 37792577 |
| Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors [ Proc Natl Acad Sci U S A, 2022, 119(5)e2113491119] | PubMed: 35091470 |
| Increased IRF9-STAT2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining GSDME-dependent pyroptosis [ J Invest Dermatol, 2022, S0022-202X(22)00096-3] | PubMed: 35148998 |
| Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor [ Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-2761] | PubMed: 34782366 |
| Preclinical characterization of a next generation brain permeable, paradox breaker BRAF inhibitor [ Clin Cancer Res, 2021, clincanres.2761.2021] | PubMed: 34782366 |
| The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop [ Sci Adv, 2021, 7(24)eabg0390] | PubMed: 34108213 |
| Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells [ Mol Cancer, 2020, 19(1):139] | PubMed: 32907612 |
| Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. [ Oncogene, 2019, 10.1038/s41388-019-1021-] | PubMed: 31558800 |
| SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma [ Int J Cancer, 2018, 143(12):3131-3142] | PubMed: 29905375 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.